In induction therapy for cryptococcal meningitis in HIV patients, which regimen is commonly recommended?

In induction therapy for cryptococcal meningitis in HIV patients, which regimen is commonly recommended?

• A. Amphotericin B (liposomal) plus flucytosine
• B. Fluconazole monotherapy
• C. Itraconazole monotherapy
• D. Voriconazole monotherapy

Answer: (A)

Induction therapy for cryptococcal meningitis aims for rapid reduction of fungal burden in the CNS to improve survival. The best regimen is liposomal amphotericin B combined with flucytosine because this pairing produces a strong synergistic fungicidal effect. Amphotericin B disrupts fungal cell membranes, while flucytosine interferes with DNA synthesis; together they clear cryptococcus from the CSF faster than either drug alone, which translates into better outcomes for HIV-associated meningitis. Using the liposomal form helps lessen nephrotoxicity and other side effects, making it feasible to treat aggressively. Fluconazole monotherapy, while important later for consolidation, acts more slowly and is associated with poorer outcomes when used as induction therapy. Itraconazole or voriconazole as monotherapy do not have proven efficacy as first-line induction in this setting and are not preferred due to limited CNS penetration and less evidence supporting their use in induction. After the initial induction phase, treatment typically proceeds to consolidation with fluconazole and then maintenance therapy, especially in patients starting or on antiretroviral therapy.

Induction therapy for cryptococcal meningitis aims for rapid reduction of fungal burden in the CNS to improve survival. The best regimen is liposomal amphotericin B combined with flucytosine because this pairing produces a strong synergistic fungicidal effect. Amphotericin B disrupts fungal cell membranes, while flucytosine interferes with DNA synthesis; together they clear cryptococcus from the CSF faster than either drug alone, which translates into better outcomes for HIV-associated meningitis. Using the liposomal form helps lessen nephrotoxicity and other side effects, making it feasible to treat aggressively.

Fluconazole monotherapy, while important later for consolidation, acts more slowly and is associated with poorer outcomes when used as induction therapy. Itraconazole or voriconazole as monotherapy do not have proven efficacy as first-line induction in this setting and are not preferred due to limited CNS penetration and less evidence supporting their use in induction. After the initial induction phase, treatment typically proceeds to consolidation with fluconazole and then maintenance therapy, especially in patients starting or on antiretroviral therapy.